VASOCON-A
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Apr 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VASOCON-A is a small-molecule ophthalmic solution approved in 1990 for treating ocular conditions, likely allergic conjunctivitis or ocular congestion based on the vasoconstrictor class naming. The mechanism of action involves vasoconstriction to reduce redness and discomfort in the eye.
LOE Approaching
Product nearing patent expiration with moderate competitive pressure (30/100) signals defensive rather than growth-oriented team dynamics and likely cost-containment focus.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect the mature, stable nature of VASOCON-A with minimal growth headcount. Career roles focus on defending market share, managing generic transition, and operational efficiency rather than expansion or innovation.
Brand ManagerSales Representative
Worked on VASOCON-A at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.